BioSim M2M: Molecules to Medicine

BioSimulytics has developed breakthrough technology combining quantum physics, computational chemistry, machine learning, and high-performance computing to boost the success rates of pharmaceutical R&D.

The BioSimulytics invention (patent EP3948877A1), is being applied to crystal structure prediction (CSP) for determining the most stable crystal structure or polymorph of a drug compound, as well as the most stable binding poses in protein-ligand complexes.Existing state-of-the-art techniques for polymorph analysis require long and painstaking experimentation by material scientists with uncertain results (